Hyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: A retrospective analysis

BMC Ophthalmology

Volumn 14, Issue 1, 2014, Pages

  Nakatake, Shunji ^a   Yoshida, Shigeo ^a   Nakao, Shintaro ^a   Arita, Ryoichi ^a   Yasuda, Miho ^a   Kita, Takeshi ^a   Enaida, Hiroshi ^a   Ohshima, Yuji ^a   Ishibashi, Tatsuro ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Hyphema; Intravitreal bevacizumab; Mitomycin C; Neovascular glaucoma; Trabeculectomy

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; ADVERSE EFFECTS; AGED; ANTAGONISTS AND INHIBITORS; FEMALE; FOLLOW UP; GLAUCOMA, NEOVASCULAR; HUMAN; HYPHEMA; INCIDENCE; INTRAOCULAR PRESSURE; INTRAVITREAL DRUG ADMINISTRATION; JAPAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; POSTOPERATIVE HEMORRHAGE; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TIME; TRABECULECTOMY; TREATMENT OUTCOME; TRENDS; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, NEOVASCULAR; HUMANS; HYPHEMA; INCIDENCE; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; JAPAN; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TRABECULECTOMY; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84901191112     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-14-55     Document Type: Article

References (30)

1. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Napoleone F, King GL, N Engl J Med 1994 331 1480 1487 10.1056/NEJM199412013312203 7526212 (Pubitemid 24356306)
2. Mitomycin-C-augmented trabeculectomy for neovascular glaucoma. A preliminary report. Mandal AK, Majji AB, Mandal SP, Das T, Jalali S, Gothwal VK, Jain SS, Nutheti R, Indian J Ophthalmol 2002 50 287 293 12532493 (Pubitemid 36019805)
3. Trabeculectomy with mitomycin C for treatment of neovascular glaucoma in diabetic patients. Kiuchi Y, Sugimoto R, Nakae K, Saito Y, Ito S, Ophthalmologica 2006 220 383 388 10.1159/000095865 17095884 (Pubitemid 44725975)
4. Mid-term effects of trabeculectomy with mitomycin C in neovascular glaucoma patients. Hyung SM, Kim SK, Korean J Ophthalmol 2001 15 98 106 11811590
5. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Sivak-Callcott JA, O'Day DM, Gass JD, Tsai JC, Ophthalmology 2001 108 1767 1776 10.1016/S0161-6420(01)00775-8 11581047 (Pubitemid 32905930)
6. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP, Ophthalmology 1998 105 232 237 10.1016/S0161-6420(98)92782-8 9479280 (Pubitemid 28090825)
7. Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma. Lim TH, Bae SH, Cho YJ, Lee JH, Kim HK, Sohn YH, Korean J Ophthalmol 2009 23 188 192 10.3341/kjo.2009.23.3.188 19794946
8. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, Otori Y, Kamei M, Kusaka S, Tano Y, Ophthalmology 2008 115 1571 1580 10.1016/j.ophtha.2008.02.026 18440643
9. Intravitreal injection of bevacizumab to treat neovascular glaucoma. Kubota T, Aoki R, Harada Y, Tou N, Tawara A, Jpn J Ophthalmol 2008 52 410 412 10.1007/s10384-008-0573-3 18991046
10. Intracameral injection of bevacizumab for the treatment of neovascular glaucoma. Wolf A, Von Jagow B, Ulbig M, Haritoglou C, Ophthalmologica 2008 226 51 56
11. Intravitreal bevacizumab for neovascular glaucoma. Vasudev D, Blair MP, Galasso J, Kapur R, Vajaranant T, J Ocul Pharmacol Ther 2009 25 453 458 10.1089/jop.2009.0036 19857107
12. Bevacizumab as adjuvant for neovascular glaucoma. Beutel J, Peters S, Luke M, Aisenbrey S, Szurman P, Spitzer MS, Yoeruek E, Grisanti S, Acta Ophthalmol 2010 88 103 109 10.1111/j.1755-3768.2008.01355.x 18811641
13. Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection. Ishibashi S, Tawara A, Sohma R, Kubota T, Toh N, Arch Ophthalmol 2010 128 1539 1545 10.1001/archophthalmol.2010.282 21149776
14. Intravitreal bevacizumab treatment for neovascular glaucoma: histopathological analysis of trabeculectomy specimens. Yoshida N, Hisatomi T, Ikeda Y, Kohno R, Murakami Y, Imaki H, Ueno A, Fujisawa K, Ishibashi T, Graefes Arch Clin Exp Ophthalmol 2011 249 1547 1552 10.1007/s00417-011-1761-2 21842129
15. Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection. Kohno R, Hata Y, Mochizuki Y, Arita R, Kawahara S, Kita T, Miyazaki M, Hisatomi T, Ikeda Y, Aiello LP, Ishibashi T, Am J Ophthalmol 2010 150 223 229 10.1016/j.ajo.2010.03. 016 20542485
16. Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C. Alkawas AA, Shahien EA, Hussein AM, J Glaucoma 2010 19 622 626 10.1097/IJG.0b013e3181ccb794 20179624
17. Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma. Saito Y, Higashide T, Takeda H, Ohkubo S, Sugiyama K, Acta Ophthalmol 2010 88 96 102 10.1111/j.1755-3768.2009. 01648.x 19775309
18. Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure. Takihara Y, Inatani M, Fukushima M, Iwao K, Iwao M, Tanihara H, Am J Ophthalmol 2009 147 912 918 10.1016/j.ajo.2008.11.015 19195639
19. Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures: a systematic review and meta-analysis. Rulli E, Biagioli E, Riva I, Gambirasio G, De Simone I, Floriani I, Quaranta L, JAMA Ophthalmol 2013 131 1573 1582 10.1001/jamaophthalmol.2013.5059 24158640
20. Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma. Takihara Y, Inatani M, Kawaji T, Fukushima M, Iwao K, Iwao M, Tanihara H, J Glaucoma 2011 20 196 201 10.1097/IJG.0b013e3181d9ce12 20440215
21. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Sugimoto Y, Mochizuki H, Okumichi H, Takumida M, Takamatsu M, Kawamata S, Kiuchi Y, Graefes Arch Clin Exp Ophthalmol 2010 248 1601 1609 10.1007/s00417-010-1406-x 20524132
22. Prognostic risk factors for failure of trabeculectomy with mitomycin C after vitrectomy. Inoue T, Inatani M, Takihara Y, Awai-Kasaoka N, Ogata-Iwao M, Tanihara H, Jpn J Ophthalmol 2012 56 464 469 10.1007/s10384-012-0171-2 22855023
23. Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy. Koleva-Georgieva DN, Sivkova NP, Terzieva D, Folia Med (Plovdiv) 2011 53 44 50 21797106
24. Cytokine signatures in atherosclerotic claudicants. DePalma RG, Hayes VW, Cafferata HT, Mohammadpour HA, Chow BK, Zacharski LR, Hall MR, J Surg Res 2003 111 215 221 10.1016/S0022-4804(03)00075-1 12850465 (Pubitemid 36808912)
25. Effect of TNF, IL-1, and IL-6 on the proliferation of human Tenon's capsule fibroblasts in tissue culture. Cunliffe IA, Richardson PS, Rees RC, Rennie IG, Br J Ophthalmol 1995 79 590 595 10.1136/bjo.79.6.590 7626577
26. Inflammatory molecules in aqueous humour and on ocular surface and glaucoma surgery outcome. Cvenkel B, Kopitar AN, Ihan A, Mediators Inflamm 2010 2010 939602 20467456
27. Intracameral tissue plasminogen activator for resolution of fibrin clots after glaucoma filtering procedures. Tripathi RC, Tripathi BJ, Park JK, Quaranta L, Steinspair K, Lehman E, Ernest JT, Am J Ophthalmol 1991 111 247 248 1899538
28. The place of sodium hyaluronate in glaucoma surgery. Wilson RP, Lloyd J, Ophthalmic Surg 1986 17 30 33 3951793 (Pubitemid 16150169)
29. Trabeculectomy with mitomycin C combined with direct cauterization of peripheral iris in the management of neovascular glaucoma. Elgin U, Berker N, Batman A, Simsek T, Cankaya B, J Glaucoma 2006 15 466 470 10.1097/01.ijg. 0000212270.27359.64 16988612 (Pubitemid 44435003)
30. Assessment of bleb morphologic features and postoperative outcomes after Ex-PRESS drainage device implantation versus trabeculectomy. Good TJ, Kahook MY, Am J Ophthalmol 2011 151 507 513 10.1016/j.ajo.2010.09.004 21236403